$1.34
+0.05 (+3.88%)
Open$1.31
Previous Close$1.29
Day High$1.34
Day Low$1.29
52W High$1.88
52W Low$0.96
Volume—
Avg Volume311.7K
Market Cap61.33M
P/E Ratio—
EPS$-1.48
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+419.4% upside
Current
$1.34
$1.34
Target
$6.96
$6.96
$5.52
$6.96 avg
$10.50
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.44M | 13.53M | 15.01M |
| Net Income | -947,825 | -765,390 | -987,033 |
| Profit Margin | -6.6% | -5.7% | -6.6% |
| EBITDA | -1,267,375 | -1,123,871 | -1,333,015 |
| Free Cash Flow | -656,212 | -624,188 | -715,122 |
| Rev Growth | +21.5% | +1.8% | +6.7% |
| Debt/Equity | 0.93 | 0.92 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |